Previous close | 1.6000 |
Open | 1.6000 |
Bid | 0.0000 |
Ask | 4.8000 |
Strike | 65.00 |
Expiry date | 2024-05-17 |
Day's range | 1.6000 - 1.6000 |
Contract range | N/A |
Volume | |
Open interest | 21 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
On May 14, 2024, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals Inc (NASDAQ:ANIP), executed a sale of 16,669 shares of the company.